Editas Capital Surpluse from 2010 to 2025
| EDIT Stock | USD 1.30 0.09 6.47% |
Capital Surpluse | First Reported 2016-03-31 | Previous Quarter 1.4 B | Current Value 1.6 B | Quarterly Volatility 438.4 M |
Check Editas Medicine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Editas Medicine's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.5 M, Interest Expense of 3 M or Selling General Administrative of 59.8 M, as well as many indicators such as Price To Sales Ratio of 3.07, Dividend Yield of 0.0 or PTB Ratio of 0.61. Editas financial statements analysis is a perfect complement when working with Editas Medicine Valuation or Volatility modules.
Editas | Capital Surpluse |
Latest Editas Medicine's Capital Surpluse Growth Pattern
Below is the plot of the Capital Surpluse of Editas Medicine over the last few years. It is Editas Medicine's Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Editas Medicine's overall financial position and show how it may be relating to other accounts over time.
| Capital Surpluse | 10 Years Trend |
|
Capital Surpluse |
| Timeline |
Editas Capital Surpluse Regression Statistics
| Arithmetic Mean | 637,408,117 | |
| Geometric Mean | 131,400,834 | |
| Coefficient Of Variation | 96.78 | |
| Mean Deviation | 529,216,242 | |
| Median | 652,464,000 | |
| Standard Deviation | 616,878,077 | |
| Sample Variance | 380538.6T | |
| Range | 1.7B | |
| R-Value | 0.90 | |
| Mean Square Error | 74026.2T | |
| R-Squared | 0.82 | |
| Slope | 117,219,145 | |
| Total Sum of Squares | 5708078.4T |
Editas Capital Surpluse History
About Editas Medicine Financial Statements
Editas Medicine shareholders use historical fundamental indicators, such as Capital Surpluse, to determine how well the company is positioned to perform in the future. Although Editas Medicine investors may analyze each financial statement separately, they are all interrelated. The changes in Editas Medicine's assets and liabilities, for example, are also reflected in the revenues and expenses on on Editas Medicine's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Capital Surpluse | 1.7 B | 854.8 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.